FDA rejects Capricor's deramiocel for Duchenne muscular dystrophy
The agency cited serious data integrity problems in a key trial. Two randomized studies had also failed to show benefit.
, updated . 1-minute read.

The Food and Drug Administration declined on Friday to approve Capricor Therapeutics’ investigational cell therapy deramiocel for Duchenne muscular dystrophy, Reuters reported. The FDA cited data integrity problems in a key trial as the reason the evidence fell short of the approval standard.
Capricor had sought approval for deramiocel to maintain arm and hand movement in people with Duchenne, a lethal inherited disorder that mostly strikes boys and leads to worsening muscle weakness, inability to move, heart problems, and early death. Capricor’s stock dropped 72% in after-hours trading. The setback puts its lead experimental product at risk and darkens the company’s business outlook, after it spent months trying to rescue the application by targeting arm and hand function.
The FDA’s outside experts voted nine to three in July that the data then available failed to show deramiocel helped Duchenne-related heart disease. Capricor subsequently resubmitted its application with fresh evidence for a more limited proposed use centered on upper limb movement.
According to STAT, Capricor ran two randomized studies that did not meet their objectives. Neither trial demonstrated that deramiocel slowed heart failure or kept arm muscles working. The treatment targeted adolescents and young adults with Duchenne who could no longer walk and have limited alternatives, but it did not benefit them.
Update, November 20, 2026
The FDA's rejection was a second complete response letter, NeurologyLive reported. The agency said deramiocel's data did not establish substantial evidence of effectiveness and cited additional clinical deficiencies that Capricor did not describe.
Capricor chief executive Linda Marbán said the company was "deeply disappointed for the boys and young men living with Duchenne and their families." She said deramiocel had met primary endpoints in two randomized, placebo-controlled trials, HOPE-2 and HOPE-3, and that Capricor stands behind its data. The company said it is reviewing the letter and will announce next steps after completing its evaluation, and that it has begun regulatory engagement in Europe and Japan.
Sources: STAT, Yahoo! Finance, NeurologyLive - Clinical Neurology News and Neurology Expert Insights
Corrections. Report an error to corrections@clinicalobserver.com. Read our corrections policy.